| 非小细胞肺癌新靶点ROS1融合基因 |
| |
| 引用本文： | 张东芳,魏万里. 非小细胞肺癌新靶点ROS1融合基因[J]. 现代肿瘤医学, 2016, 0(2): 310-313. DOI: 10.3969/j.issn.1672-4992.2016.02.044 |
| |
| 作者姓名： | 张东芳 魏万里 |
| |
| 作者单位： | 昆明医科大学附属第三医院/云南省肿瘤医院病理科，云南 昆明 650118 |
| |
| 摘 要： | 非小细胞肺癌(non-small cell lung cancer，NSCLC) 是造成人类死亡最多的恶性肿瘤之一,其五年生存率一直徘徊在20%以下。自肺癌领域首个分子靶向药物吉非替尼上市以来，靶向药物因其低毒、高效、便于给药的临床特点，己逐渐成为治疗NSCLC的重要选择之一。因此，筛选和证实肿瘤驱动基因已经成为未来靶向药物研发的重中之重。近来，越来越多的学者把焦点转移到ROS1融合基因上，并且已经有相关数据及研究表明ROS1融合基因被证实为NSCLC新的有潜力的治疗靶点，因此我们现就ROS1融合基因在NSCLC中的相关研究进展做一综述。
|
| 关 键 词： | 非小细胞肺癌 ROS1 融合基因 基因重排 |
Non - small cell lung cancer novel target ROS1 fusion |
| |
| Zhang Dongfang,Wei Wanli. Non - small cell lung cancer novel target ROS1 fusion[J]. Journal of Modern Oncology, 2016, 0(2): 310-313. DOI: 10.3969/j.issn.1672-4992.2016.02.044 |
| |
| Authors: | Zhang Dongfang Wei Wanli |
| |
| Affiliation: | Department of Pathology，The Third Affiliated Hospital of Kunming Medical University/The Tumor Hospital of Yunnan Province，Yunnan Kunming 650118，China. |
| |
| Abstract: | Non - small cell lung cancer(NSCLC)is one of the biggest killers all over the world,and its five - year survival rate low than 20% . Screening and confirmed the tumor drive genes has become a top priority of the future re-search and development of targeted drugs. Recently,more and more scholars focus shifted to ROS1 gene fusion,and have the relevant data and studies have shown that ROS1 fusion genes have been confirmed for NSCLC new potential therapeutic targets. In this review,we summarize the research progress of ROS1 fusion gene in NSCLC. |
| |
| Keywords: | non - small cell lung cancer ROS1 fusion oncogenes gene rearrange - ment |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
